Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8957720rdf:typepubmed:Citationlld:pubmed
pubmed-article:8957720lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:8957720lifeskim:mentionsumls-concept:C0085082lld:lifeskim
pubmed-article:8957720lifeskim:mentionsumls-concept:C0035648lld:lifeskim
pubmed-article:8957720lifeskim:mentionsumls-concept:C0004610lld:lifeskim
pubmed-article:8957720lifeskim:mentionsumls-concept:C0028902lld:lifeskim
pubmed-article:8957720lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:8957720lifeskim:mentionsumls-concept:C0199176lld:lifeskim
pubmed-article:8957720lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:8957720lifeskim:mentionsumls-concept:C1136254lld:lifeskim
pubmed-article:8957720pubmed:issue5lld:pubmed
pubmed-article:8957720pubmed:dateCreated1997-4-2lld:pubmed
pubmed-article:8957720pubmed:abstractTextThe authors analyzed 27 breakthrough bacteremias occurring during ofloxacin prophylaxis in afebrile neutropenia over 7 years in 9989 admissions and 979 bacteremic and fungemic episodes in a National Cancer Center in Bratislava, Slovak Republic. The most frequently isolated organisms in breakthrough bacteremias were gram-positive (71.3%), mainly coagulase-negative staphylococci (41.3%), enterococci (9.2%) and Corynebacteria (9.2%), followed by gram-negative rods-Pseudomonas aeruginosa (13.2%) and Stenotrophomonas maltophilia (9.2%). The outcome of breakthrough bacteremias during ofloxacin prophylaxis was not associated with the underlying disease, neutropenia, catheter insertion or resistance, but only with multiple risk factors. A higher failure rate was observed in those patients having a catheter infected with a resistant organism and during neutropenia. No patients with Hickman catheter were included in the study. Patients with mixed breakthrough bacteremia due to gram-negative and gram-positive organisms had higher failure rates than those with monomicrobial bacteremia. Catheter extraction and rapid institution of intravenous antibiotics in combination should be administered in breakthrough bacteremia.lld:pubmed
pubmed-article:8957720pubmed:languageenglld:pubmed
pubmed-article:8957720pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8957720pubmed:citationSubsetIMlld:pubmed
pubmed-article:8957720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8957720pubmed:statusMEDLINElld:pubmed
pubmed-article:8957720pubmed:monthOctlld:pubmed
pubmed-article:8957720pubmed:issn1120-009Xlld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:TruplJJlld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:KrcmeryVVJrlld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:SpanikSSlld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:KorelRRlld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:LackaJJlld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:PichnaPPlld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:DrgonaLLlld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:HelpianskaLLlld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:OravcovaEElld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:StudenaMMlld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:KukuckovaEElld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:RusnakovaVVlld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:IlavskaIIlld:pubmed
pubmed-article:8957720pubmed:authorpubmed-author:Demitrovicova...lld:pubmed
pubmed-article:8957720pubmed:issnTypePrintlld:pubmed
pubmed-article:8957720pubmed:volume8lld:pubmed
pubmed-article:8957720pubmed:ownerNLMlld:pubmed
pubmed-article:8957720pubmed:authorsCompleteYlld:pubmed
pubmed-article:8957720pubmed:pagination387-93lld:pubmed
pubmed-article:8957720pubmed:dateRevised2009-8-4lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:meshHeadingpubmed-meshheading:8957720-...lld:pubmed
pubmed-article:8957720pubmed:year1996lld:pubmed
pubmed-article:8957720pubmed:articleTitleBacteremia and fungemia occurring during antimicrobial prophylaxis with ofloxacin in cancer patients: risk factors, etiology and outcome.lld:pubmed
pubmed-article:8957720pubmed:affiliationDept. of Medicine, University of Trnava, Bratislava, Slovak Republic.lld:pubmed
pubmed-article:8957720pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8957720pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8957720lld:pubmed